Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection

Background: The hepatitis B and D virus (HBV/HDV) hepatocyte entry inhibitor bulevirtide (BLV) has been available in Europe since July 2020, after the registrational trial MYR202. Real-life data on the efficacy and safety of BLV are sparse. Methods: We have analysed the course of treatment with BLV...

Descripción completa

Detalles Bibliográficos
Autores principales: Herta, Toni, Hahn, Magdalena, Maier, Melanie, Fischer, Janett, Niemeyer, Johannes, Hönemann, Mario, Böhlig, Albrecht, Gerhardt, Florian, Schindler, Aaron, Schumacher, Jonas, Berg, Thomas, Wiegand, Johannes, van Bömmel, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143982/
https://www.ncbi.nlm.nih.gov/pubmed/35631038
http://dx.doi.org/10.3390/pathogens11050517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143982/
https://www.ncbi.nlm.nih.gov/pubmed/35631038
http://dx.doi.org/10.3390/pathogens11050517

Ejemplares similares